Subscribe To
MCRB / Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
![Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/u/8/transcript25-1786219.jpg)
MCRB News
![Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/z/c/transcript19-2140531.jpg)
By Seeking Alpha
November 4, 2023
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric more_horizontal
![Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy](https://cdn.snapi.dev/images/v1/g/9/image-1418835107-2047241.jpg)
By Seeking Alpha
September 1, 2023
Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully con more_horizontal
![Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates](https://cdn.snapi.dev/images/v1/g/0/biotech27-1879653.jpg)
By Zacks Investment Research
May 9, 2023
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 more_horizontal
![Seres Gets FDA Approval And The Share Price Goes Down! Seres Gets FDA Approval And The Share Price Goes Down!](https://cdn.snapi.dev/images/v1/a/w/image-1436530254-1868654.jpg)
By Seeking Alpha
May 3, 2023
Seres Gets FDA Approval And The Share Price Goes Down!
Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weir more_horizontal
![Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength? Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?](https://cdn.snapi.dev/images/v1/w/f/biotech16-1837250.jpg)
By Zacks Investment Research
April 14, 2023
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal
![Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last? Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?](https://cdn.snapi.dev/images/v1/v/g/biotech39-1807192.jpg)
By Zacks Investment Research
March 22, 2023
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimat more_horizontal
![Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/u/8/transcript25-1786219.jpg)
By Seeking Alpha
March 7, 2023
Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric S more_horizontal
![Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates](https://cdn.snapi.dev/images/v1/6/7/biotech1-1785620.jpg)
By Zacks Investment Research
March 7, 2023
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the nu more_horizontal